Avalo Therapeutics (AVTX) Other Non-Current Liabilities (2015 - 2025)

Avalo Therapeutics (AVTX) has 11 years of Other Non-Current Liabilities data on file, last reported at $18.0 million in Q4 2025.

• For the quarter ending Q4 2025, Other Non-Current Liabilities rose 121.67% year-over-year to $18.0 million; the trailing twelve-month figure through Dec 2025 stood at $18.0 million (up 121.67% YoY), and the FY2025 full-year result was $18.0 million, up 121.67% from the prior year.
• Other Non-Current Liabilities for Q4 2025 stood at $18.0 million, up from $117000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $18.0 million in Q4 2025 and bottomed at $117000.0 in Q3 2025.
• The 5-year median for Other Non-Current Liabilities is $1.9 million (2022), against an average of $4.3 million.
• Peak annual rise in Other Non-Current Liabilities reached 767.29% in 2025, while the deepest fall reached 99.01% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $2.3 million in 2021, then retreated by 25.54% to $1.7 million in 2022, then declined by 20.16% to $1.4 million in 2023, then surged by 494.44% to $8.1 million in 2024, then soared by 121.67% to $18.0 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $18.0 million (Q4 2025), $117000.0 (Q3 2025), and $10.3 million (Q2 2025), per Business Quant data.

Peer Comparison